Head-to-head evidence
fenoterol vs Salbutamol HFA-134a
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
fenoterol
Developed by Boehringer Ingelheim
NCT02177370 · Phase 3 · terminated
This was a randomized, double-blind, active-controlled crossover study, but it enrolled only 19 participants and one of its two primary measures is a laboratory receptor-density biomarker rather than a direct asthma outcome, and no results have been posted.
Salbutamol HFA-134a
Developed by GlaxoSmithKline
NCT06261957 · Phase 3 · completed
The study randomized 477 adults and used quadruple blinding with an active salbutamol comparator. Its primary endpoint was the number of participants with adverse events, but no results or statistical comparison are posted, so the outcome is currently unknown.
Next expected readout: February 2027 · NCT06433921 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fenoterol's landscape · Salbutamol HFA-134a's landscape